Rockefeller Capital Management
LUCD icon

Rockefeller Capital Management’s Lucid Diagnostics LUCD Stock Holding History

Rockefeller Capital Management’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-625
Closed -$681 – 4812
2025
Q4 		$681 Hold
625
– – ﹤0.01% 4497
2025
Q3 		$631 Buy
+625
New +$683 ﹤0.01% 4239

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Rockefeller Capital Management's LUCD Position: Q1 2026 in Review

Rockefeller Capital Management sold out of Lucid Diagnostics (LUCD) in Q1 2026, closing a stake of 625 shares — an estimated $681 sold.

Rockefeller Capital Management first reported a position in LUCD in Q3 2025 and held it in 2 quarters. The position peaked at $681 in Q4 2025. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Rockefeller Capital Management reported no remaining Lucid Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Rockefeller Capital Management sold 625 Lucid Diagnostics shares in Q1 2026, an estimated $681.
  • Rockefeller Capital Management first reported a position in Lucid Diagnostics in Q3 2025 and held it in 2 quarters.
  • Rockefeller Capital Management's Lucid Diagnostics position peaked at $681 in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.